Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
46.7 USD | -0.04% | +4.50% | +4.36% |
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- With an expected P/E ratio at 71.12 and 58.01 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+4.36% | 934M | C | ||
+18.46% | 7.66B | C- | ||
+22.71% | 3.85B | B- | ||
-17.95% | 3.14B | C- | ||
-19.93% | 1.35B | B | ||
-30.65% | 1.18B | - | ||
-34.81% | 911M | - | ||
-26.60% | 840M | - | C+ | |
-15.56% | 726M | - | ||
-12.45% | 597M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SLP Stock
- Ratings Simulations Plus, Inc.